BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 33576380)

  • 1. Fine-tuning the cardiac O-GlcNAcylation regulatory enzymes governs the functional and structural phenotype of the diabetic heart.
    Prakoso D; Lim SY; Erickson JR; Wallace RS; Lees JG; Tate M; Kiriazis H; Donner DG; Henstridge DC; Davey JR; Qian H; Deo M; Parry LJ; Davidoff AJ; Gregorevic P; Chatham JC; De Blasio MJ; Ritchie RH
    Cardiovasc Res; 2022 Jan; 118(1):212-225. PubMed ID: 33576380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphoinositide 3-kinase (p110α) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction.
    Prakoso D; De Blasio MJ; Qin C; Rosli S; Kiriazis H; Qian H; Du XJ; Weeks KL; Gregorevic P; McMullen JR; Ritchie RH
    Clin Sci (Lond); 2017 Jun; 131(12):1345-1360. PubMed ID: 28487469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. O-GlcNAcase overexpression reverses coronary endothelial cell dysfunction in type 1 diabetic mice.
    Makino A; Dai A; Han Y; Youssef KD; Wang W; Donthamsetty R; Scott BT; Wang H; Dillmann WH
    Am J Physiol Cell Physiol; 2015 Nov; 309(9):C593-9. PubMed ID: 26269457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy targeting cardiac phosphoinositide 3-kinase (p110α) attenuates cardiac remodeling in type 2 diabetes.
    Prakoso D; De Blasio MJ; Tate M; Kiriazis H; Donner DG; Qian H; Nash D; Deo M; Weeks KL; Parry LJ; Gregorevic P; McMullen JR; Ritchie RH
    Am J Physiol Heart Circ Physiol; 2020 Apr; 318(4):H840-H852. PubMed ID: 32142359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E2f1 deletion attenuates infarct-induced ventricular remodeling without affecting O-GlcNAcylation.
    Dassanayaka S; Brittian KR; Jurkovic A; Higgins LA; Audam TN; Long BW; Harrison LT; Militello G; Riggs DW; Chitre MG; Uchida S; Muthusamy S; Gumpert AM; Jones SP
    Basic Res Cardiol; 2019 May; 114(4):28. PubMed ID: 31152247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. O-GlcNAc Transferase Promotes Compensated Cardiac Function and Protein Kinase A O-GlcNAcylation During Early and Established Pathological Hypertrophy From Pressure Overload.
    Zhu WZ; El-Nachef D; Yang X; Ledee D; Olson AK
    J Am Heart Assoc; 2019 Jun; 8(11):e011260. PubMed ID: 31131693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excessive
    Umapathi P; Mesubi OO; Banerjee PS; Abrol N; Wang Q; Luczak ED; Wu Y; Granger JM; Wei AC; Reyes Gaido OE; Florea L; Talbot CC; Hart GW; Zachara NE; Anderson ME
    Circulation; 2021 Apr; 143(17):1687-1703. PubMed ID: 33593071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardioprotective O-GlcNAc signaling is elevated in murine female hearts via enhanced O-GlcNAc transferase activity.
    Narayanan B; Sinha P; Henry R; Reeves RA; Paolocci N; Kohr MJ; Zachara NE
    J Biol Chem; 2023 Dec; 299(12):105447. PubMed ID: 37949223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excess protein O-GlcNAcylation and the progression of diabetic cardiomyopathy.
    Fricovsky ES; Suarez J; Ihm SH; Scott BT; Suarez-Ramirez JA; Banerjee I; Torres-Gonzalez M; Wang H; Ellrott I; Maya-Ramos L; Villarreal F; Dillmann WH
    Am J Physiol Regul Integr Comp Physiol; 2012 Oct; 303(7):R689-99. PubMed ID: 22874425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression of O-GlcNAc cycling enzymes in human breast cancers.
    Krześlak A; Forma E; Bernaciak M; Romanowicz H; Bryś M
    Clin Exp Med; 2012 Mar; 12(1):61-5. PubMed ID: 21567137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E2F1 Transcription Factor Regulates O-linked N-acetylglucosamine (O-GlcNAc) Transferase and O-GlcNAcase Expression.
    Muthusamy S; Hong KU; Dassanayaka S; Hamid T; Jones SP
    J Biol Chem; 2015 Dec; 290(52):31013-24. PubMed ID: 26527687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene and protein expression of O-GlcNAc-cycling enzymes in human laryngeal cancer.
    Starska K; Forma E; Brzezińska-Błaszczyk E; Lewy-Trenda I; Bryś M; Jóźwiak P; Krześlak A
    Clin Exp Med; 2015 Nov; 15(4):455-68. PubMed ID: 25315705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure.
    Lunde IG; Aronsen JM; Kvaløy H; Qvigstad E; Sjaastad I; Tønnessen T; Christensen G; Grønning-Wang LM; Carlson CR
    Physiol Genomics; 2012 Feb; 44(2):162-72. PubMed ID: 22128088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. O-GlcNAc transferase affects the signal transduction of β1 adrenoceptor in adult rat cardiomyocytes by increasing the O-GlcNAcylation of β1 adrenoceptor.
    Cao H; Hu Y; Zhu X; Yao N; Gu J; Wang Y; Zhu W
    Biochem Biophys Res Commun; 2020 Jul; 528(1):71-77. PubMed ID: 32471715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feedback Regulation of
    Lin CH; Liao CC; Chen MY; Chou TY
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33801653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes-associated dysregulation of O-GlcNAcylation in rat cardiac mitochondria.
    Banerjee PS; Ma J; Hart GW
    Proc Natl Acad Sci U S A; 2015 May; 112(19):6050-5. PubMed ID: 25918408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging roles of protein O-GlcNAcylation in cardiovascular diseases: Insights and novel therapeutic targets.
    Bolanle IO; Riches-Suman K; Williamson R; Palmer TM
    Pharmacol Res; 2021 Mar; 165():105467. PubMed ID: 33515704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained Increases in Cardiomyocyte Protein
    Ha CM; Bakshi S; Brahma MK; Potter LA; Chang SF; Sun Z; Benavides GA; He L; Umbarkar P; Zou L; Curfman S; Sunny S; Paterson AJ; Rajasekaran NS; Barnes JW; Zhang J; Lal H; Xie M; Darley-Usmar VM; Chatham JC; Wende AR
    J Am Heart Assoc; 2023 Oct; 12(19):e029898. PubMed ID: 37750556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OGT and OGA expression in postmenopausal skeletal muscle associates with hormone replacement therapy and muscle cross-sectional area.
    Toivonen MH; Pöllänen E; Ahtiainen M; Suominen H; Taaffe DR; Cheng S; Takala T; Kujala UM; Tammi MI; Sipilä S; Kovanen V
    Exp Gerontol; 2013 Dec; 48(12):1501-4. PubMed ID: 24365779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting of oxidative stress with coenzyme Q10 counteracts exaggerated diabetic cardiomyopathy in a mouse model of diabetes with diminished PI3K(p110α) signaling.
    De Blasio MJ; Huynh K; Qin C; Rosli S; Kiriazis H; Ayer A; Cemerlang N; Stocker R; Du XJ; McMullen JR; Ritchie RH
    Free Radic Biol Med; 2015 Oct; 87():137-47. PubMed ID: 25937176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.